DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
A Combination Study of Durvalumab plus Olaparib in an Unselected Population with Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Approved For Public Release